• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

March 12, 2018
Company Drug/Device Medical Condition Status
Seattle Genetics, Inc. SGN-CD48A Relapsed or refractory multiple myeloma Phase I trial initiated enrolling 75 subjects
Daiichi Sankyo Company, Ltd. DS-8201 HER2-expressing advanced colorectal cancer Phase II trial initiated enrolling 50 subjects in North America, Europe and Japan
GTx, Inc. Enobosarm Stress urinary incontinence (SUI) Phase II trial initiated enrolling 18 female subjects
InflaRx IFX-1 Moderate or severe Hidradenitis Suppertiva (HS) Phase IIb trials initiated enrolling 175 subjects in the U.S., Germany, Greece, Denmark and the Netherlands
Aimmune Therapeutics, Inc. AR101 Peanut allergy Phase III trials initiated enrolling 850 subjects ages 4-49
Vanda Pharmaceuticals, Inc. Hetlioz Jet lag disorder Phase III trials initiated enrolling 318 subjects
Biohaven Pharmaceutical Holding Company Ltd. Zydis ODT formulation of rimegepant Migraine Phase III trials initiated enrolling 850 subjects
Bioverativ, Inc BIVV009 Cold agglutinin disease Phase III trials initiated
MeiraGTx AAOO2 Achromatopsia PRIME designation grated by the EMA
Tocagen Inc. Toca 511 (vocimagene amiretrorepvec) & Toca FC (flucytosine) Glioma Orphan drug designated granted by the EMA
InVivo Therapeutics Holdings Corp. Neuro-Spinal Scaffold Acute spinal cord injury (SCI) FDA approval granted
Polyganics Liver and Pancreas Sealant Patch Fluid leakage after hepato-pancreato-biliary (HPB) procedures FDA breakthrough device designation granted

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing